Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Vertex Awarding Young Researchers $750,000 To Focus on Cystic Fibrosis

NOVEMBER 01, 2017
James Radke
Vertex Pharmaceuticals wants more young researchers studying cystic fibrosis (CF). And they are willing to pay for it.

Today, Vertex announced a new $750,000 research grant program for clinical scientists to establish CF research programs in their own lab and another $125,000 grant for researchers being mentored in CF labs.

The Independent Research Innovation Award provides $750,000 dispersed over 3 years to support newly independent faculty members in order to establish their own research programs in CF. Vertex will provide up to 2 awards each year moving forward.

To be eligible for this award, the person must have a PhD, MD, or equivalent (obtained within 15 years). The person should also be in control of their own research direction and lab space in which there is an established publication record in the field of CF. For more details on this award, click here.

The Mentored Research Innovation Award which provides up to $125,000 over 2 years. Vertex will provide up to 4 of these awards each year moving forward.

To be eligible for this award, the person must have a PhD, MD, or equivalent (obtained within 8 years) and currently being mentored by an established CF researcher. For more details on this award, click here.

Applicants may apply now through January 8, 2018.

In a news release, David Altshuler, M.D., Ph.D., Executive Vice President, Global Research and Chief Scientific Officer of Vertex. “Supporting the development of young physician researchers and scientists is critical to continued advancement of our understanding of the disease, and to ensure people living with cystic fibrosis have the best care for the future.”

CF is a life-threatening hereditary disorder that damages in patients’ lungs and digestive systems. Common symptoms include frequent lung infections, heavy coughing and difficulty breathing.

The rare disease is caused by a faulty or absent cystic fibrosis transmembrane conductance regulator (CFTR) protein. Vertex has 2 treatments approved for CF patients [Kalydeco (ivacaftor) and Orkami (lumacaftor ivacaftor)] as well as many other treatments in development.

Vertex’s commitment to the CF community is well documented and continues to grow. Over the next 5 years, the company plans to provide up to $10 million in grant money.

Image courtesy wikimedia commons.                  

For the latest research news, follow Rare Disease Report on  FacebookTwitter, and LinkedIn.





 

Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.